Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
Characterizing Dopamine D2 and D3 Receptor Binding in Treatment Resistant Depression
1 other identifier
observational
45
1 country
1
Brief Summary
It is estimated that 30% of individuals with Major Depressive Disorder (MDD) fail to respond to conventional antidepressant medication which accounts for over 1 million Canadians in their lifetime. Treatment resistant depression (TRD) patients also have greater psychiatric and medical comorbidity, poorer quality of life and increased suicidal ideation. Yet, there are few treatment strategies available to target TRD and there is a significant lack of evidence about how TRD differs from treatment-responsive depression. This proposal represents the first study to elucidate the neurobiology of TRD with a focus on dopamine receptor function throughout the brain, in order to inform treatment development and clinical characterization of TRD.The ultimate goal of this unique study is to characterize striatal and extrastriatal dopamine D2 and D3 receptor binding potential in patients with TRD, non-resistant MDD and healthy controls. The primary hypothesis is that TRD patients will exhibit greater D2/D3 receptor binding potential compared to non-TRD patients in the following regions of interest: dorsolateral prefrontal cortex, orbitofrontal cortex, and ventral striatum. Secondarily, non-TRD patients will also demonstrate increased binding potential compared to healthy controls in the same brain regions. Whole brain analyses will allow us to take an exploratory approach to other brain regions that may differentiate TRD from non-TRD patients. Participants will be assessed at St. Michael's Hospital (SMH) and the Centre for Addiction and Mental Health (CAMH), which are within a 10 minute driving distance of each other. There will be 3 study visits following written informed consent. Eligibility will be confirmed at a screening visit at SMH where demographic information, including age, sex, education, and medication history will be obtained, as well as the administration of a structured Mini-International Neuropsychiatric Interview (MINI) for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Axis I diagnoses (Sheehan et al, 2015), and an HRSD-17. Within two weeks of the screening visit, participants will undergo a structural magnetic resonance imaging (MRI) scan at SMH prior to the positron-emission tomography (PET) scan at CAMH. The order of the PHNO scans will be counterbalanced.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 15, 2018
CompletedFirst Posted
Study publicly available on registry
May 25, 2018
CompletedStudy Start
First participant enrolled
August 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2028
March 16, 2026
February 1, 2026
2.3 years
May 15, 2018
March 12, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Dopamine potential
TRD patients exhibit greater D2/D3 receptor binding potential
3 years
Study Arms (3)
Treatment Resistant Depression
Unmedicated Individuals with Treatment Resistant Depression
Major Depressive Disorder
Unmedicated Individuals with Major Depressive Disorder
Healthy Control
healthy controls with no previous psychiatric disorders
Interventions
PET scans and PHNO scans
Eligibility Criteria
Participants will be recruited from clinics at St. Michael's Hospital and the Centre for Addiction and Mental Health as well as from research programs at the two sites, which have ongoing MDD clinical trials where patients are required to be unmedicated prior to initiating treatment.
You may qualify if:
- DSM-5 criteria for a Major Depressive Episode (MDE) within a MDD, confirmed through MINI diagnosis (Sheehan et al, 2015)
- Age between 25 and 55 years
- Hamilton Depression Rating Scale - 17 item (HRSD-17; Hamilton, 1960) \> 14 (moderate to severe symptoms)
- Free of psychotropic medications for at least 5 half-lives before PET scanning
- Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)
- For non-resistant patients: Previous history of response to an antidepressant, in order to increase signal to noise between resistant and non-resistant patients
- Ages between 25 and 55 years
- Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)
You may not qualify if:
- Pregnancy/lactation
- Medical condition requiring immediate investigation or treatment
- Recent (\< 6 months)/current history of drug abuse/dependence
- Lifetime history of psychosis, other Axis I comorbidities are allowable
- Use of any psychotropic use within 5 half-lives before the PET scanning
- For non-resistant patients: Failure of \> 2 antidepressant treatments of adequate dose and duration for current MDE.
- Pregnancy/lactation
- Medical condition requiring immediate investigation or treatment
- Lifetime history of any psychiatric disorder
- Lifetime history of receiving an antidepressant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Unity Health Torontolead
- Centre for Addiction and Mental Healthcollaborator
Study Sites (1)
Unity Health Toronto
Toronto, Ontario, M5B 1M4, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sakina J Rizvi, PhD
Unity Health Toronto
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2018
First Posted
May 25, 2018
Study Start
August 22, 2025
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2028
Last Updated
March 16, 2026
Record last verified: 2026-02